Transformational cell therapies for patients with pancreatic disease

OUR PIPELINE OF CELL THERAPIES IS CHANGING THE OUTLOOK FOR PATIENTS WITH CHRONIC PANCREATITIS AND TYPE 1 DIABETES.

Matthew Lehman,

Chief Executive Officer (Koligo Therapeutics Inc.) and Executive Director

Proven biotech & cell therapy executive
NASDAQ-listed Prima Biomed, CSE-listed M Pharmaceutical, private CRO SPRI Clinical Trials
Clinical research & manufacturing scale-up expertise
MS Columbia; BA Louisville

Stuart Williams, PhD,

Chief Technology Officer (Koligo Therapeutics Inc.) and Executive Director

Division chief, Bioficial Heart, Cardiovascular Innovation Institude
300+ publications & 16 issued US patents in cell & tissue engineering
Experienced academic-industry partner: founded three biotech companies
PhD cell biology University of Delaware, postdoc Yale School of Medicine

Peter James,

Non-Executive Director

30+ years’ experience in emerging technologies
Extensive experience as Chair, Non-Executive Director and CEO of both publicly listed and private companies

Jethro Marks,

Non-Executive Director

Co-founder and CEO of The Nile and Mercury Retail, a leading Australian eCommerce service provider
15+ years’ experience in marketing

Robert Clisdell,

Non-Executive Director

Head of Bergen Capital LLC Australian office
Extensive experience as director for publicly traded corporations
15+ years’ experience in banking, finance and accounting as an investment banker with Credit Suisse and Caliburn Partnership
Graduate Diploma in Applied Finance and Investment from FINSIA